study_id,author,first_dose_only,location_id,location_id2,location_name,location_name2,vac_before_booster,vaccine_developer,variant,symptom_severity,severity,sample_size,age_start,age_end,efficacy_mean,efficacy_lower,efficacy_upper,booster,vemt,mean_time_since_vaccination,start_interval,end_interval,sev_severity,mid_point1,mid_point,study_id2,e_mean,se,mean_logit,sd_logit,in_var
533,Hogan A,0,95,95,United Kingdom,UK 2 Omicron,"",AstraZeneca,Omicron,infection,infection,,10,60,0.095,0.078,0.115,0,0,,12,25,infection,18.5,18.5,533&UK 2 Omicron&Omicron&infection&10&60,0.01,0.00943877551020408,-4.59511985013459,0.953411667697382,1.02930047093133
533,Hogan A,0,95,95,United Kingdom,UK 2 Omicron,"",AstraZeneca,Omicron,infection,infection,,10,60,0.047,0.038,0.058,0,0,,26,34,infection,30,30,533&UK 2 Omicron&Omicron&infection&10&60,0.01,0.00510204081632653,-4.59511985013459,0.515357658214801,1.4
